Valneva SE/€VLA

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Valneva SE

Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.

Ticker

€VLA

Primary listing

PAR

Industry

Biotechnology

Employees

713

Valneva SE Metrics

BasicAdvanced
€551M
-
-€0.54
1.10
-

Bulls say / Bears say

Valneva received the first marketing authorization for its chikungunya vaccine, IXCHIQ®, in Brazil, marking a significant milestone in expanding its market presence in endemic regions. (globenewswire.com)
The company reported positive Phase 2 booster results for its Lyme disease vaccine candidate, VLA15, developed in partnership with Pfizer, indicating strong immune responses across all age groups. (pfizer.com)
Valneva secured up to $41.3 million in additional funding from CEPI to enhance global access to its chikungunya vaccine, supporting post-marketing trials and potential label extensions. (delveinsight.com)
Analysts have slashed Valneva's revenue estimates for 2025 by 13%, indicating a more pessimistic outlook on the company's financial performance. (simplywall.st)
The company has postponed debt payments, deferring reimbursements of its first $100 million loan tranche to January 2026, which may signal cash flow concerns. (tipranks.com)
Short interest in Valneva's stock increased by 191.4% as of March 15, 2025, suggesting growing bearish sentiment among investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €VLA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs